A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

24 Oct 2024 Status changed from active, no longer recruiting to completed.
14 Oct 2024 According to an AstraZeneca media release, based on results from DESTINY-Lung02 and DESTINY-Lung05 trials, the Enhertu has received conditional approval from China's NMPA as a monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer whose tumours have activating HER2 mutations and who have received a prior systemic therapy. Full approval for this indication will depend on the clinical benefit from the confirmatory trial.
04 Jun 2024 Results assessing updated efficacy and safety results from the final analysis of DESTINY-Lung02 were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com